Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
| ▸ | PDE2A | O00408 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14382808 | 0.93 | L3MBTL1 (0.53) | MAPTTP53RXFP1SIRT2SIRT1 | |
| SCHEMBL14382846 | 0.88 | MAPT (0.57) | MAPTTP53RXFP1SIRT2SIRT1 | |
| SCHEMBL5508936 | 0.88 | L3MBTL1 (0.57) | RXFP1GAAL3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL14382791 | 0.85 | L3MBTL1 (0.58) | RXFP1GAAL3MBTL1CYP3A4CYP1A2 | |
| SCHEMBL14382748 | 0.85 | L3MBTL1 (0.50) | MAPTTP53RXFP1SMN1; SMN2NPC1 | |
| SCHEMBL5513980 | 0.84 | SIRT2 (0.56) | MAPTTP53RXFP1SIRT2SIRT1 | |
| SCHEMBL5513984 | 0.84 | SIRT2 (0.56) | MAPTTP53RXFP1SIRT2SIRT1 | |
| SCHEMBL14382680 | 0.83 | MAPT (0.53) | MAPTTP53RXFP1SMN1; SMN2NPC1 | |
| SCHEMBL5514113 | 0.83 | SIRT2 (0.54) | MAPTTP53RXFP1SIRT2SIRT1 | |
| SCHEMBL5518664 | 0.83 | RPS6KB1 (0.56) | MAPTTP53RXFP1SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097438-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2004-05-20 | — | — | US | claimed |
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2004-04-29 | — | — | US | claimed |
| EP-1400241-A1 | FUSED CYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-03-24 | — | — | EP | claimed |
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2003-03-13 | — | — | US | claimed |
| EP-1162196-A1 | FUSED-RING COMPOUNDS AND USE THEREOF AS DRUGS | JAPAN TOBACCO INC. (JP) | 2001-12-12 | — | — | EP | claimed |
| US-7285551-B2 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20070032497-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-7112600-B1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2006-09-26 | — | — | US | disclosed |
| US-6770666-B2 | A THERAPEUTIC AGENT FOR TREATING HEPATITIS C, BASED ON POLYMERASE INHIBITORY ACTIVITY | JAPAN TOBACCO INC. (JP) | 2004-08-03 | — | — | US | disclosed |
| US-20040097438-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2004-05-20 | — | — | US | disclosed |
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1400241-A1 | FUSED CYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2003-03-13 | — | — | US | disclosed |
| EP-1162196-A1 | FUSED-RING COMPOUNDS AND USE THEREOF AS DRUGS | JAPAN TOBACCO INC. (JP) | 2001-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | HAVCR2, ZC3HAV1, POLR1C | MAPT 3967/4885TP53 89/4885RXFP1 4865/4885 |
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, HLA-C | MAPT 3928/4885TP53 166/4885RXFP1 4816/4885 |
| US-20070032497-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, HLA-C | MAPT 3203/4885TP53 132/4885RXFP1 4848/4885 |
| US-20040097438-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, SLC10A1 | MAPT 4439/4885TP53 358/4885RXFP1 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.